Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial.

Fiche publication

Date publication

janvier 2026

Journal

Crohn's & colitis 360

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Reinisch W, Peyrin-Biroulet L, D'Haens G, Sturm A, Anderson JK, Messina I, Arikan D, Zimmerman-Bennett A, Parmentier J, Feng T, D'Cunha R, Lazar A, Louis E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42027411

Résumé

ABBV-154 is an antibody-drug conjugate of adalimumab and a proprietary glucocorticoid receptor modulator. This phase 2b randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of ABBV-154 versus placebo in patients with moderately to severely active Crohn's disease who had inadequate response to or were intolerant of prior biologic therapy.